Cargando…

Dose-Dependent Outcome of EBV Infection of Humanized Mice Based on Green Raji Unit (GRU) Doses

Humanized mouse models are used as comprehensive small-animal models of EBV infection. Previously, infectious doses of EBV used in vivo have been determined mainly on the basis of TD(50) (50% transforming dose), which is a time-consuming process. Here, we determined infectious doses of Akata-EBV-GFP...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Haiwen, Zhong, Ling, Zhang, Wanlin, Zhang, Shanshan, Hong, Junping, Zhou, Xiang, Zhang, Xinyu, Feng, Qisheng, Chen, Yixin, Zeng, Yi-Xin, Xu, Miao, Krummenacher, Claude, Zhang, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624110/
https://www.ncbi.nlm.nih.gov/pubmed/34834989
http://dx.doi.org/10.3390/v13112184
Descripción
Sumario:Humanized mouse models are used as comprehensive small-animal models of EBV infection. Previously, infectious doses of EBV used in vivo have been determined mainly on the basis of TD(50) (50% transforming dose), which is a time-consuming process. Here, we determined infectious doses of Akata-EBV-GFP using green Raji units (GRUs), and characterized dose-dependent effects in humanized mice. We defined two outcomes in vivo, including an infection model and a lymphoma model, following inoculation with low or high doses of Akata-EBV-GFP, respectively. Inoculation with a low dose induced primary B cells to become lymphoblastoid cell lines in vitro, and caused latent infection in humanized mice. In contrast, a high dose of Akata-EBV-GFP resulted in primary B cells death in vitro, and fatal B cell lymphomas in vivo. Following infection with high doses, the frequency of CD19(+) B cells decreased, whereas the percentage of CD8(+) T cells increased in peripheral blood and the spleen. At such doses, a small part of activated CD8(+) T cells was EBV-specific CD8(+) T cells. Thus, GRUs quantitation of Akata-EBV-GFP is an effective way to quantify infectious doses to study pathologies, immune response, and to assess (in vivo) the neutralizing activity of antibodies raised by immunization against EBV.